We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




High-Frequency Thermotherapy for Liver Cancer

By HospiMedica staff writers
Posted on 11 Jul 2001
A new weapon against liver cancer that uses high-frequency energy to generate heat to destroy cancerous tissue also employs a saline solution to avoid dehydration of tissues, thereby allowing the heat to spread over a wider area. More...
The treatment, which is minimally invasive, offers an alternative to surgery for inoperable patients.

The radio frequency tissue ablation (RFTA) procedure lasts no longer than an hour and requires only local anesthesia. The needle electrode is monitored by sonography or magnetic resonance imaging (MRI) as it is introduced into the tumor. Patients are able to go home the next day. No complications or side effects requiring treatment have yet been observed. The interior of the needle electrode is hollow and the needle tip has microscopically fine openings and water depositories. During treatment, physiologic saline solution in tiny amounts penetrates into the tissue through these holes. This saline solution markedly increases electric conductivity for high-frequency current at the target area. The system was developed by scientists at the Berchtold Company (Tuttlingen, Germany; www.berchtold.de), in collaboration with university clinics in Germany.

Numerous studies have shown no differences in the survival rate of patients who underwent surgery and those who had the thermotherapy. In one ultrasound-guided study, 75% of all tumors were destroyed with the RFTA procedure. The remaining 25% were larger than 5cm, so the size of the tumor appears to be the limiting factor of therapy success. Tumors smaller than 40 mm were all destroyed. At six months follow-up, 11 of the 15 patients who were initially in complete remission were still in remission.




Related Links:
Berchtold

Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Resorbable Bovine Collagen Membrane
GenDerm
New
Breast Imaging Monitor
Barco Coronis Onelook MDMC-32133 32MP
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.